IceCure Medical (ICCM) Common Equity (2020 - 2026)

IceCure Medical (ICCM) has 7 years of Common Equity data on file, last reported at $8.5 million in Q1 2026.

• Quarterly Common Equity changed N/A year-over-year to $8.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8.5 million (changed N/A YoY) and the FY2025 annual result came in at $9.1 million, up 31.15% from the prior year.
• Common Equity fell to $8.5 million in Q1 2026 per ICCM's latest filing, from $9.1 million in the prior quarter.
• Across five years, Common Equity topped out at $25.4 million in Q4 2022 and bottomed at $6.9 million in Q4 2024.
• The 5-year median for Common Equity is $9.1 million (2025), against an average of $12.4 million.
• The widest annual swing landed in 2023, when Common Equity slumped 52.16%; it then surged 31.15% in 2025.
• Tracing ICCM's Common Equity over 5 years: stood at $25.4 million in 2022, then slumped by 52.16% to $12.2 million in 2023, then tumbled by 43.26% to $6.9 million in 2024, then surged by 31.15% to $9.1 million in 2025, then declined by 6.15% to $8.5 million in 2026.
• Per Business Quant, the three latest ICCM Common Equity figures stand at $8.5 million (Q1 2026), $9.1 million (Q4 2025), and $6.9 million (Q4 2024).

Peer Comparison